Drugs / HER-2 pulsed DC1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02336984 | Jun 2014 → Apr 2016 | breast cancer | H. Lee Moffitt Cancer Center and Research Institute | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05325632 | Oct 2021 → Feb 2027 expected | HER2 positive breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER-2 pulsed DC1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05325632 ↗ |
| Known as | Dendritic Cell (DC1) vaccine | “The purpose of the study is to find out if an investigational drug called Dendritic Cell (DC1) vaccine added to standard neoadjuvant (given before main treatment) therapy can...” NCT05325632 ↗ |
| Modality | Vaccine | “HER-2/Neu Pulsed DC1 Vaccine” NCT02336984 ↗ |
| Route | Intrathecal | “Treatment included IT delivery of cDC1, 6 times weekly” PMID 39636623 ↗ Feb 2025 |